No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate + flutamide Sensitive: A1 - Approval goserelin acetate + flutamide Sensitive : A1	goserelin acetate + flutamide Sensitive: A1 - Approval goserelin acetate + flutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide 6-month depot Sensitive: A1 - Approval leuprolide 6-month depot Sensitive : A1	leuprolide 6-month depot Sensitive: A1 - Approval leuprolide 6-month depot Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprorelin depot Sensitive: A1 - Approval leuprorelin depot Sensitive : A1	leuprorelin depot Sensitive: A1 - Approval leuprorelin depot Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2

Prostate Cancer

Associations(495)

Associations
(495)